非小细胞肺癌术后辅助化疗的共识  

Postoperative Adjuvant Chemotherapy for Non-Small Cell Lung Cancer

作　　者：陈芳[1] 陆舜[1] 

机构地区：[1]上海市胸科医院上海市肺部肿瘤临床医学中心,上海200030

出　　处：《中国肿瘤》2006年第5期319-321,共3页China Cancer

摘　　要：近年来有关非小细胞肺癌术后辅助化疗的治疗标准发生了显著变化,越来越多的前瞻性、大样本随机临床试验和多项荟萃分析均证实辅助化疗,特别是新一代化疗药物的含铂联合方案能显著提高化疗反应和总体生存期,降低死亡危险比,且毒性反应均可耐受。因此,对于完整手术后的非小细胞肺癌,特别是ⅠB～Ⅱ期的患者采用辅助化疗是合理治疗方案。Recently the standard of postoperative adjuvant chemotherapy for non-small cell lung cancer has significantly changed.More and more, large scale and prospective randomized clinical trials anti Meta-analyses have proved that adjuvant chemotherapy, especially new generation of. chemotherapeutic agents combined with platinum can significantly improve the median and overall survival. It also can decrease the hazard ratio for death anti its toxicity is tolerable.Therefore adjuvant chemotherapy is a optimal therapy for patients with non-small cell lung cancer completely resected, especially in stage Ⅰ B and Ⅱ.

关 键 词：非小细胞肺癌 辅助化疗 

分 类 号：R734.2[医药卫生—肿瘤]